Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Theradex
Sanofi
Ascentage Pharma Group Inc.
University of Pittsburgh
Karyopharm Therapeutics Inc
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center